Filippo de Marinis - Concepedia

Author

Filippo de Marinis

Also Known As

Cesare Gridelli, De Marinis, Filippo, F De Marinis, F Romano, F de Marinis, F. DE MARINIS, F. De Marinis, F. de Marinis, FILIPPO DE MARINIS, Federico Cappuzzo

725

Publications

45.6K

Citations

H-Index

126

Concepts

All Affiliations

European Institute of Oncology Istituti di Ricovero e Cura a Carattere Scientifico Carlo Forlanini Hospital Azienda Ospedaliera S.Giuseppe Moscati University of Milan

About

Filippo de Marinis is an author at European Institute of Oncology specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	131	19.8K
2	Health Sciences	22	47	8.2K
3	Public Health	4	4	192
4	Engineering	1	1	29
5	Social Sciences	1	1	27

Filippo de Marinis

235

Publications

40.5K

Citations

H-Index

Page 1

	Year	Citations
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell, Enric Carcereny, Radj Gervais, The Lancet Oncology OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm	2012	5.5K
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, The Lancet Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsPathology	2016	4.7K
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Journal of Clinical Oncology	2008	3.2K
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Journal of Clinical Oncology	2004	2.4K
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer Yi‐Long Wu, Masahiro Tsuboi, Jie He, New England Journal of Medicine	2020	1.7K
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, New England Journal of Medicine	2020	1.6K
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, The Lancet MedicineMetronomic TherapyPhase Iii TrialBronchial NeoplasmCancer Treatment	2009	1.4K
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, New England Journal of Medicine	2020	1K
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer Jürgen Wolf, Takashi Seto, Ji‐Youn Han, New England Journal of Medicine	2020	957
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Filippo de Marinis, Monica Rinaldi, Journal of Clinical Oncology	2002	890

Page 1